PSMA-targeting alpha-Radiation therapy with 225Actinium-PSMA-617: Dosimetry, toxicity and duration of tumor-control
To evaluate the potential of 225Ac-PSMA617 for PSMA-targeting alpha-therapy of poor-prognosis advanced-stage mCRPC patients.
KRATOCHWIL Clemens;
BRUCHERTSEIFER Frank;
GIESEL Frederik;
APOSTOLIDIS Christos;
HABERKORN Uwe;
MORGENSTERN Alfred;
2017-10-25
SPRINGER
JRC106777
1619-7070,
Additional supporting files
File name | Description | File type | |